PBH

Prestige is a low-capex, brand-led OTC health portfolio that throws off cash well in excess of its reported earnings. FY2026 generated $258M of operating cash against just $11.2M of capex (~$247M free cash flow) on $1.09B of revenue, with a 54.7% gross margin, 28.4% operating margin and 17.5% net margin — staples-like economics. Management is funneling that cash to shareholders, spending $156M on buybacks (up 203%) and shrinking the share count 4.1%, with no dividend. At $48.03 the stock trades at 12.3x diluted EPS of $3.91 and 2.1x sales — a discount that prices in stagnation, while the cash generation says otherwise.

The headline blemish is the top line: revenue fell 4.3% and net income 11.3% in FY2026, breaking a multi-year run of ~$1.1B revenue. But the 10-K attributes a meaningful part of that to supply-chain/manufacturing constraints — explicitly flagging product shortages 'particularly eye care products' that 'negatively impacted our results.' That is a fixable, arguably transient cause rather than evidence of brand decay, and the December 2025 Pillar5 deal (vertically integrating a Clear Eyes ophthalmic supplier) directly targets that bottleneck. The pending Foundation Consumer Brands purchase (Breathe Right and other OTC brands, expected to close 1H FY2027) is squarely on-strategy: acquiring under-managed brands to reinvigorate, the same playbook that built the portfolio.